Dipna Pharmachem Ltd reported a 170.3% year-on-year increase in net profit to ₹263.19 lakh for the financial year ended March 31, 2026. The company’s revenue from operations for the year rose to ₹1,291.09 crore, compared to ₹1,249.30 crore in the previous year. For the quarter ended March 31, 2026, the company recorded a net profit of ₹17.86 lakh, a decline from ₹104.21 lakh in the preceding quarter, while revenue stood at ₹20.25 crore.

The Board of Directors, in its meeting held on July 2, 2026, approved the audited standalone financial results for the quarter and year ended March 31, 2026. The results were reviewed by the audit committee and are based on the financial statements prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. This marks the company’s first adoption of Ind AS.

Financial Performance

The company’s total income for FY26 stood at ₹1,291.09 crore, up from ₹1,249.30 crore in FY25. Total expenses for the year increased to ₹1,255.64 crore from ₹1,235.10 crore in the previous year. Profit before tax for the year rose to ₹354.48 lakh from ₹142.02 lakh, while the tax expense for the year was ₹91.29 lakh.

For the quarter ended March 31, 2026, total income was ₹20.50 crore, and total expenses were ₹18.28 crore. The profit before tax for the quarter was ₹22.28 lakh, with a tax expense of ₹4.42 lakh. Earnings per share (EPS) for the year increased to ₹1.00 from ₹0.41 in the previous year.

Segment Reporting

Dipna Pharmachem operates across two reportable segments: Steel and Chemicals. The Chemicals segment contributed ₹58.19 crore to the total revenue for the year, while the Steel segment contributed ₹70.89 crore. The Steel segment reported a profit of ₹866.83 lakh for the year, whereas the Chemicals segment reported a loss of ₹512.35 lakh.

Capital Structure and Cash Flows

The company’s paid-up equity share capital increased to ₹2,628.92 lakh as of March 31, 2026, from ₹2,404.53 lakh in the previous year, following the issuance of equity shares and share warrants. Cash and cash equivalents at the end of the year stood at ₹86.30 lakh, compared to ₹42.57 lakh at the beginning of the year. Net cash flow from financing activities was positive at ₹1,880.03 lakh, primarily driven by proceeds from the issue of equity shares and share warrants.

Statutory Auditor’s Report

M/s. Devadiya & Associates, Chartered Accountants, the statutory auditors of the company, issued an unmodified opinion on the audited standalone financial results for the half-year and financial year ended March 31, 2026. The audit was conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013.

Key Financial Metrics for FY26

Dipna Pharmachem Limited accepted the resignation of Nandish Shaileshbhai Jani from the position of Non-Executive and Independent Director effective June 10, 2026. The resignation was submitted due to personal reasons, and the company confirmed there are no other material factors behind the decision.

The disclosure was made to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company received confirmation from Jani that the reasons stated in his resignation letter are exhaustive.

Jani holds directorships in other listed entities, including Magenta Lifecare Limited and AKI India Limited, where he serves as an Independent Director. His roles include chairperson and member positions on key board committees such as Audit, Nomination and Remuneration, and Stakeholders' Relationship committees.

The resignation details were provided in an annexure to the regulatory filing, confirming the effective date and the nature of the director's prior roles. The board acknowledged the resignation and requested the exchange to take note of the change.

Resignation Details